Study presents main causes of child mortality in Brazil, Mexico

A study published this week analyzed the main causes of death among children aged 5 to 14 years in Brazil and Mexico. The researchers found that communicable or nutritional diseases accounted for 14% of deaths among Brazilian children, while non-communicable ailments represented 45% of deaths, with cancer, neurological conditions, and pneumonia as some of the top deadly causes. On the other hand, communicable/nutritional and non-communicable diseases made up 12% and 53% of deaths among children in Mexico respectively, with cancer, neurological, and cardiovascular conditions among the leading causes.

Most of these diseases present a downward trend in recent years, with average annual rates of reduction ranging from around 0.5% for cancer in both nations to 12% for malaria in Brazil. However, some ailments are on an upwards trend, with average annual rates of increase of 3% for neurological conditions in Brazil and 3% for cardiovascular diseases in Mexico.


Related news
France-based Sanofi-Aventis saw its diabetes drug Soliqua (insulin glargine + lixisenatide) obtain registration from Colombia’s National Food and Drug Surveillance Institute (INVIMA), according to GBI analysis.
After Eli Lilly announced at the end of last year its plans to close its only factory in Brazil, as GBI reported, general manager in Brazil Karla Alcázar shed light on the company’s plans in the country.
According to sources, Switzerland-based Novartis is planning to divest its cardiometabolic products in Argentina, namely Diovan (valsartan), Exforge (amlodipine/valsartan), and Galvus (vildagliptin).
According to the 2018 annual report published by Germany-based major Merck KGaA, drug sales in Latin America reached EUR 661 million (USD 750 million), accounting for 11% of the Healthcare division's turnover.
  • 1552032868458
  • Brazil,Mexico,Argentina,Colombia,Peru,Venezuela,Chile,Cuba,Uruguay,Paraguay,Ecuador ,Costa Rica,El Salvador,Panama,Bolivia ,Guatemala,Puerto Rico ,Dominican Republic,Honduras,Haiti,Nicaragua,Belize
  • Company
Marking 20 years since generic drug regulations were first introduced in Brazil, Luiz Borgonovi, president of Brazil-based generics giant EMS, published an account of the sector.
Recent news
Alfonso Ramírez Cuéllar, president of the Budget Commission in Mexico’s House of Representatives, urged the Ministry of Finance and Public Credit (SHCP) to disclose the names of 10 pharmaceutical companies that have received contracts for 80% of the consolidated drug purchases during previous administrations.
Colombia’s National Food and Drug Surveillance Institute (INVIMA) last month approved Switzerland-based Roche’s hemophilia drug Hemlibra (emicizumab), as GBI analysis found.
France-based Sanofi-Aventis saw its diabetes drug Soliqua (insulin glargine + lixisenatide) obtain registration from Colombia’s National Food and Drug Surveillance Institute (INVIMA), according to GBI analysis.
According to GBI analysis, Ecuador’s National Agency for Health Regulation, Control and Surveillance (ARCSA) last month granted registration to Switzerland-based Ferring’s oral anti-inflammatory Cortiment (budesonide).
Switzerland-based giant Novartis AG has officially launched its Ultibro (indacaterol glycopyrronium bromide, powder for inhalation, hard capsules) and Seebri (glycopyrronium bromide, powder for inhalation, hard capsules) chronic obstructive pulmonary disease (COPD) maintenance therapies into the Chinese market.
  • 1552880244053
  • China
  • Drug
Sino-U.S. biotech Xynomic Pharma announced the receipt of clinical trial approvals in China, Spain, and Poland for its histone deacetylase (HDAC) inhibitor abexinostat in combination with pazopanib for patients with renal cell carcinoma (RCC).
  • 1552879902162
  • China
  • Drug
China-based vaccines specialist CanSino Biotechnology Inc., is moving to hold an initial public offering (IPO) of 5,725,200 H shares to the Hong Kong Stock Exchange (HKSE) Main Board from March 28, 2019 alongside another 51,523,400 H shares to the global market, with the price range currently at HKD 21 to HKD 22 per share.
Analytics Snapshot

Understand market developments and maintain your competitive advantage.